Personnel Information

写真a

ASAHINA Yasuhiro


Job title

Professor

Campus Career 【 display / non-display

  • 2012.04
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Endowed Departments, Department of Liver Disease Control, Professor
 

Published Papers & Misc 【 display / non-display

  1. Shun Kaneko, Yasuhiro Asahina, Mina Nakagawa, Miyako Murakawa, Yasunari Miyazaki, Takahiro Asakage, Shohei Fukuda, Takeshi Namiki, Yoshito Kano, Masashi Nagata, Jun Tsuchiya, Masato Miyoshi, Fukiko Kitahata-Kawai, Sayuri Nitta, Yasuhiro Itsui, Sei Kakinuma, Ryuichi Okamoto. Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatol Res. 2023.01; ( PubMed, DOI )

  2. Shuhei Sekiguchi, Kaoru Tsuchiya, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Leona Osawa, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Masayuki Kurosaki, Namiki Izumi. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.(Online ahead of print.) Cancer Rep (Hoboken). 2022.03; e1613. ( PubMed, DOI )

  3. Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Yuki Tanaka, Shun Ishido, Kento Inada, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi , Yasuhiro Asahina, Ryuichi Okamoto, Namiki Izumi. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice Investigational New Drugs. 2021.10;

  4. Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Yuki Tanaka, Shun Ishido, Kento Inada, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Namiki Izumi. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Invest New Drugs. 2021.09; ( PubMed, DOI )

  5. Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2021.03; ( PubMed, DOI )

  6. Yuki Tahata, Hayato Hikita, Satoshi Mochida, Norifumi Kawada, Nobuyuki Enomoto, Akio Ido, Hitoshi Yoshiji, Daiki Miki, Yoichi Hiasa, Yasuhiro Takikawa, Ryotaro Sakamori, Masayuki Kurosaki, Hiroshi Yatsuhashi, Ryosuke Tateishi, Yoshiyuki Ueno, Yoshito Itoh, Taro Yamashita, Tatsuya Kanto, Goki Suda, Yasunari Nakamoto, Naoya Kato, Yasuhiro Asahina, Kentaro Matsuura, Shuji Terai, Kazuhiko Nakao, Masahito Shimizu, Taro Takami, Norio Akuta, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021.01; 56 (1): 67-77. ( PubMed, DOI )

  7. Mina Nakagawa, Nobutoshi Nawa, Eiko Takeichi, Taro Shimizu, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Takeo Fujiwara, Mamoru Watanabe, Yujiro Tanaka, Yasuhiro Asahina, . Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol. 2020.10; 55 (10): 990-999. ( PubMed, DOI )

  8. Yasuhiro Asahina, Chun-Jen Liu, Edward Gane, Yoshito Itoh, Norifumi Kawada, Yoshiyuki Ueno, Jin Youn, Chen-Yu Wang, Joe Llewellyn, Takuma Matsuda, Anuj Gaggar, Hongmei Mo, Hadas Dvory-Sobol, Gerald Crans, Wan-Long Chuang, Pei-Jer Chen, Nobuyuki Enomoto. Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. Hepatol Res. 2020.10; 50 (10): 1109-1117. ( PubMed, DOI )

  9. Yasuhiro Asahina, and Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection, 2019 update; protective effect of antiviral therapy against hepatocarcinogenesis. Hepatol Res. 2020.07; 50 (7): 775-790. ( PubMed, DOI )

  10. Ryoichi Ando, Yasuhiro Asahina, Kazuaki Chayama, Naoki Hiramatsu, Toru Ikegami, Namiki Izumi, Kan Kikuchi, Kazuhiko Koike, Masayuki Kurosaki, Satoshi Mochida, Fumitaka Suzuki, Tetsuo Takehara, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hiroshi Yotsuyanagi; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020.07; 50 (7): 791-816. ( PubMed, DOI )

  11. Tetsuo Takehara, Kazuaki Chayama, Masayuki Kurosaki, Hiroshi Yatsuhashi, Yasuhito Tanaka, Naoki Hiramatsu, Naoya Sakamoto, Yasuhiro Asahina, Akito Nozaki, Toshikazu Nakano, Yosuke Hagiwara, Hiroko Shimizu, Hiroki Yoshida, Yuhan Huang, Michael Biermer, Leen Vijgen, Norio Hayashi. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol. 2020.06; 55 (6): 640-652. ( PubMed, DOI )

  12. Sakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Koji Yamashita, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mao Okada, Wan Wang, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One. 2020.04; 15 (4): e0231828. ( PubMed, DOI )

  13. Ryoichi Ando, Yasuhiro Asahina, Kazuaki Chayama, Naoki Hiramatsu, Toru Ikegami, Namiki Izumi, Kan Kikuchi, Kazuhiko Koike, Masayuki Kurosaki, Satoshi Mochida, Fumitaka Suzuki, Tetsuo Takehara, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hiroshi Yotsuyanagi; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection: 2019 Update. Hepatol Res. 2020.04;

  14. Sayuri Nitta, Kazuaki Takahashi, Fukiko Kawai-Kitahata, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe, Yasuhiro Asahina. Time course alterations of virus sequences and immunoglobulin titers in a chronic hepatitis E patient. Hepatol Res. 2020.04; 50 (4): 524-531. ( PubMed, DOI )

  15. Sato A, Kakinuma S, Miyoshi M, Kamiya A, Tsunoda T, Kaneko S, Tsuchiya J, Shimizu T, Takeichi E, Nitta S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Koshikawa N, Seiki M, Nakauchi H, Asahina Y, Watanabe M. Vasoactive Intestinal Peptide Derived From Liver Mesenchymal Cells Mediates Tight Junction Assembly in Mouse Intrahepatic Bile Ducts. Hepatology communications. 2020.02; 4 (2): 235-254. ( PubMed, DOI )

  16. Sayuri Nitta, Kazuaki Takahashi, Fukiko Kawai-Kitahata, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Miyako Murakawa, Yasuhiro Istui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe, Yasuhiro Asahina. Time course alterations of virus sequences and immunoglobulin titers in a chronic hepatitis E patient Hepatology Research. 2020; 50 (4): 524-531.

  17. Wan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa, Mao Okada, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi. Sorafenib-Regorafenib sequential therapy in Japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and post-regorafenib therapies in real world practice. Cancers (Basel). 2019.10; 11 (10): E1517. ( PubMed, DOI )

  18. Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shun Kaneko, Jun Tsuchiya, Ayako Sato, Masato Miyoshi, Tomoyuki Tsunoda, Emi Inoue-Shinomiya, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Minoru Tanabe, Emiko Sugawara, Akira Takemoto, Hidenori Ojima, Michiie Sakamoto, Masaru Muraoka, Shinichi Takano, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe. Comprehensive genetic analysis of cholangiolocellular carcinoma with a coexistent hepatocellular carcinoma-like area and metachronous hepatocellular carcinoma. Hepatol. Res.. 2019.07; ( PubMed, DOI )

  19. Emi Inoue-Shinomiya, Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Masato Miyoshi, Sayuri Nitta, Fukiko Kawai-Kitahata, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Kazumoto Murata, Masashi Mizokami, Mamoru Watanabe. Association of serum interferon-λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. Hepatol. Res.. 2019.05; 49 (5): 500-511. ( PubMed, DOI )

  20. Akira Doi, Hayato Hikita, Yugo Kai, Yuki Tahata, Yoshinobu Saito, Tasuku Nakabori, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Asako Murayama, Sayuri Nitta, Yasuhiro Asahina, Hiroshi Suemizu, Tomohide Tatsumi, Takanobu Kato, Tetsuo Takehara. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. J. Gastroenterol.. 2019.05; 54 (5): 449-458. ( PubMed, DOI )

  21. Sayuri Nitta, Yasuhiro Asahina, Takanobu Kato, Jun Tsuchiya, Emi Inoue-Shinomiya, Ayako Sato, Tomoyuki Tsunoda, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Hayato Hikita, Tetsuo Takehara, Mamoru Watanabe. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep. 2019.04; 9 (1): 5722. ( PubMed, DOI )

  22. Tomoyuki Tsunoda, Sei Kakinuma, Masato Miyoshi, Akihide Kamiya, Shun Kaneko, Ayako Sato, Jun Tsuchiya, Sayuri Nitta, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Tsuyoshi Sogo, Haruki Komatsu, Ryutaro Mukouchi, Ayano Inui, Tomoo Fujisawa, Hiromitsu Nakauchi, Yasuhiro Asahina, Mamoru Watanabe. Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.[Epub ahead of print] J. Hepatol.. 2019.03; ( PubMed, DOI )

  23. Masato Miyoshi, Sei Kakinuma, Akihide Kamiya, Tomoyuki Tsunoda, Jun Tsuchiya, Ayako Sato, Shun Kaneko, Sayuri Nitta, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Hiromitsu Nakauchi, Yasuhiro Asahina, Mamoru Watanabe. LIM homeobox 2 promotes interaction between human iPS-derived hepatic progenitors and iPS-derived hepatic stellate-like cells. Sci Rep. 2019.02; 9 (1): 2072. ( PubMed, DOI )

  24. Seishin Azuma, Yasuhiro Asahina, Sei Kakinuma, Keiko Azuma, Masato Miyoshi, Emi Inoue, Tomoyuki Tsunoda, Ayako Sato, Shun Kaneko, Hiroko Nagata, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Makoto Tomita, Mina Nakagawa, Mamoru Watanabe. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. [Epub ahead of print] Dig Dis. 2019.01; 1-8. ( PubMed, DOI )

  25. Yasuhiro Asahina, Yoshito Itoh, Yoshiyuki Ueno, Yasushi Matsuzaki, Yasuhiro Takikawa, Hiroshi Yatsuhashi, Takuya Genda, Fusao Ikeda, Takuma Matsuda, Hadas Dvory-Sobol, Deyuan Jiang, Benedetta Massetto, Anu O Osinusi, Diana M Brainard, John G McHutchison, Norifumi Kawada, Nobuyuki Enomoto. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018.09; 38 (9): 1552-1561. ( PubMed, DOI )

  26. Maekawa Shinya, Sato Mitsuaki, Kuratomi Natsuhiko, Inoue Taisuke, Suzuki Yuichiro, Tatsumi Akihisa, Miura Mika, Matsuda Shuya, Muraoka Masaru, Nakakuki Natsuko, Amemiya Fumitake, Takano Shinichi, Fukasawa Mitsuharu, Nakayama Yasuhiro, Yamaguchi Tatsuya, Sato Tadashi, Sakamoto Minoru, Murakawa Miyako, Nakagawa Mina, Asahina Yasuhiro, Enomoto Nobuyuki. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C J. Gastroenterol. 2018.06; 53 (6): 780-786. ( ichushi )

  27. Wai-Kay Seto, Yasuhiro Asahina, Todd T Brown, Cheng-Yuan Peng, Carol Stanciu, Dzhamal Abdurakhmanov, Fehmi Tabak, Tuan T Nguyen, Wan-Long Chuang, Tetsuro Inokuma, Fusao Ikeda, Teresa Antonia Santantonio, François Habersetzer, Alnoor Ramji, Audrey H Lau, Vithika Suri, John F Flaherty, Hongyuan Wang, Anuj Gaggar, G Mani Subramanian, Shrikant Mukewar, Maurizia R Brunetto, Scott Fung, Henry Lik-Yuen Chan. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.[Epub ahead of print] Clin. Gastroenterol. Hepatol. 2018.06; ( PubMed, DOI )

  28. Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Takaya Takeguchi, Yuko Takeguchi, Mao Okada, Wan Wang, Yohei Kubota, Tomoyuki Goto, Yasuyuki Komiyama, Mayu Higuchi, Kenta Takaura, Tsuguru Hayashi, Hitomi Takada, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Yoshiro Himeno, Namiki Izumi. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol. Res. 2018.05; 48 (6): 442-450. ( PubMed, DOI )

  29. Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina. Reply to: "Imaging Basis of AFP and WFA+M2BP as Indicators of the risk of HCC after SVR". J. Hepatol. 2018.03; 68 (3): 607-608. ( PubMed, DOI )

  30. Asahina Yasuhiro, Itoh Yoshito, Ueno Yoshiyuki, Matsuzaki Yasushi, Takikawa Yasuhiro, Yatsuhashi Hiroshi, Genda Takuya, Ikeda Fusao, Matsuda Takuma, Huang K. C., Massetto Benedetta, Osinusi Anu O., Brainard Diana M., McHutchison John G., Kawada Norifumi, Enomoto Nobuyuki. Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients with Chronic HCV Genotype 2 Infection HEPATOLOGY. 2017.10; 66 638A.

  31. Kaneko Shun, Kakinuma Sei, Asahina Yasuhiro, Kamiya Akihide, Miyoshi Masato, Tsunoda Tomoyuki, Inoue-Shinomiya Emi, Nitta Sayuri, Sato Ayako, Asano Yu, Nagata Hiroko, Kawai-Kitahata Fukiko, Murakawa Miyako, Itsui Yasuhiro, Nakagawa Mina, Azuma Seishin, Watanabe Mamoru. A novel culture model for coinfection of hepatitis B and hepatitis C viruses using human induced pluripotent stem cell-derived hepatic cells for analyses of changes in host-innate immune responses HEPATOLOGY. 2017.10; 66 69A.

  32. Murakawa Miyako, Asahina Yasuhiro, Nagata Hiroko, Nakagawa Mina, Kakinuma Sei, Nitta Sayuri, Kawai-Kitahata Fukiko, Otani Satoshi, Kaneko Shun, Miyoshi Masato, Tsunoda Tomoyuki, Asano Yu, Sato Ayako, Itsui Yasuhiro, Azuma Seishin, Nouchi Toshihiko, Furumoto Yohei, Asano Tooru, Chuganji Yoshimichi, Tohda Shuji, Watanabe Mamoru. ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin Hepatology Research. 2017.10; 47 (11): 1212-1218. ( ichushi )

  33. Nitta Sayuri, Murakawa Miyako, Kato Takanobu, Sato Ayako, Tsunoda Tomoyuki, Miyoshi Masato, Asano Yu, Kaneko Shun, Nagata Hiroko, Kawai-Kitahata Fukiko, Itsui Yasuhiro, Nakagawa Mina, Azuma Seishin, Kakinuma Sei, Asahina Yasuhiro. The analysis of NS5A Resistance-Associated Substitutions (RAS): In vitro study of NS5A recombinant hepatitis C in infectious cell culture system for various RAS detected after treatment failure in chronic hepatitis C patients HEPATOLOGY. 2017.10; 66 480A.

  34. Murakawa Miyako, Asahina Yasuhiro, Nakagawa Mina, Nitta Sayuri, Kawai-Kitahata Fukiko, Nagata Hiroko, Kaneko Syun, Asano Yu, Miyoshi Masato, Tsunoda Tomoyuki, Inoue-Shinomiya Emi, Sato Ayako, Itsui Yasuhiro, Kakinuma Sei, Azuma Seishin, Watanabe Mamoru. On-treatment higher levels of alpha-fetoprotein and M2BPGi are associated with development of hepatocellular carcinoma during nucleos(t)ide analog therapy in patients with HBV chronic infection HEPATOLOGY. 2017.10; 66 507A.

  35. Nakagawa Mina, Asahina Yasuhiro, Nagata Hiroko, Kaneko Shun, Kawai-Kitahata Fukiko, Murakawa Miyako, Nitta Sayuri, Itsui Yasuhiro, Azuma Seishin, Kakinuma Sei, Tanaka Yujiro, Watanabe Mamoru. Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - propensity score-matched analysis of a prospective database HEPATOLOGY. 2017.10; 66 38A-39A.

  36. Azuma Seishin, Asahina Yasuhiro, Kakinuma Sei, Azuma Keiko, Watanabe Mamoru. Diabetic retinopathy as a risk factor associated with development of hepatocellular carcinoma in non-alcoholic fatty liver disease JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 2017.09; 32 158.

  37. Tamaki N, Kurosaki M, Kusakabe A, Orito E, Joko K, Kojima Y, Kimura H, Uchida Y, Hasebe C, Asahina Y, Izumi N, Japanese Red Cross Hospital Liver Study Group.. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon. Journal of viral hepatitis. 2017.08; 24 (8): 672-678. ( PubMed, DOI )

  38. Goto Fumio, Kakinuma Sei, Miyoshi Masato, Tsunoda Tomoyuki, Kaneko Shun, Sato Ayako, Asano Yu, Otani Satoshi, Azuma Seishin, Nagata Hiroko, Kawai-Kitahata Fukiko, Murakawa Miyako, Nitta Sayuri, Itsui Yasuhiro, Nakagawa Mina, Asahina Yasuhiro, Watanabe Mamoru. Bone morphogenetic protein-4 modulates proliferation and terminal differentiation of fetal hepatic stem/progenitor cells Hepatology Research. 2017.08; 47 (9): 941-952. ( ichushi )

  39. Miyako Murakawa, Yasuhiro Asahina, Fukiko Kawai-Kitahata, Mina Nakagawa, Sayuri Nitta, Satoshi Otani, Hiroko Nagata, Shun Kaneko, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhito Tanaka, Sayuki Iijima, Kaoru Tsuchiya, Namiki Izumi, Shuji Tohda, Mamoru Watanabe. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. [Epub ahead of print] J. Med. Virol.. 2017.07; 89 (7): 1241-1247. ( PubMed, DOI )

  40. Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina, Ayako Sato, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Toshihiko Nouchi, Hideki Sakai, Makoto Tomita, Mamoru Watanabe, . Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol.. 2017.06; ( PubMed, DOI )

  41. Kentaro Matsuura, Hiromi Sawai, Kazuho Ikeo, Shintaro Ogawa, Etsuko Iio, Masanori Isogawa, Noritomo Shimada, Atsumasa Komori, Hidenori Toyoda, Takashi Kumada, Tadashi Namisaki, Hitoshi Yoshiji, Naoya Sakamoto, Mina Nakagawa, Yasuhiro Asahina, Masayuki Kurosaki, Namiki Izumi, Nobuyuki Enomoto, Atsunori Kusakabe, Eiji Kajiwara, Yoshito Itoh, Tatsuya Ide, Akihiro Tamori, Misako Matsubara, Norifumi Kawada, Ken Shirabe, Eiichi Tomita, Masao Honda, Shuichi Kaneko, Sohji Nishina, Atsushi Suetsugu, Yoichi Hiasa, Hisayoshi Watanabe, Takuya Genda, Isao Sakaida, Shuhei Nishiguchi, Koichi Takaguchi, Eiji Tanaka, Junichi Sugihara, Mitsuo Shimada, Yasuteru Kondo, Yosuke Kawai, Kaname Kojima, Masao Nagasaki, Katsushi Tokunaga, Yasuhito Tanaka, . Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. 2017.05; 152 (6): 1383-1394. ( PubMed, DOI )

  42. Miyako Murakawa, Yasuhiro Asahina, Hiroko Nagata, Mina Nakagawa, Sei Kakinuma, Sayuri Nitta, Fukiko Kawai-Kitahata, Satoshi Otani, Shun Kaneko, Masato Miyoshi, Tomoyuki Tsunoda, Yu Asano, Ayako Sato, Yasuhiro Itsui, Seishin Azuma, Toshihiko Nouchi, Yohei Furumoto, Tooru Asano, Yoshimichi Chuganji, Shuji Tohda, Mamoru Watanabe. ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin. Hepatol. Res.. 2017.01; ( PubMed, DOI )

  43. Hiroko Nagata, Mina Nakagawa, Yuki Nishimura-Sakurai, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Fumio Goto, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Naoko Tojo, Shuji Tohda, Yasuhiro Asahina, Mamoru Watanabe, . Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016.11; 10 (6): 956-964. ( PubMed, DOI )

  44. Hitomi Takada, Kaoru Tsuchiya, Yutaka Yasui, Natsuko Nakakuki, Nobuharu Tamaki, Shoko Suzuki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Med. 2016.11; 5 (11): 3111-3120. ( PubMed, DOI )

  45. Sayuri Nitta, Yasuhiro Asahina, Mami Matsuda, Norie Yamada, Ryuichi Sugiyama, Takahiro Masaki, Ryosuke Suzuki, Nobuyuki Kato, Mamoru Watanabe, Takaji Wakita, Takanobu Kato. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016.10; 6 34652. ( PubMed, DOI )

  46. Masato Miyoshi, Sei Kakinuma, Yoko Tanabe, Koji Ishii, Tian-Cheng Li, Takaji Wakita, Yukio Tsuura, Hideki Watanabe, Yasuhiro Asahina, Mamoru Watanabe, Takaaki Ikeda. Chronic Hepatitis E Infection in a Persistently Immunosuppressed Patient Unable to Be Eliminated after Ribavirin Therapy. Intern. Med.. 2016.10; 55 (19): 2811-2817. ( PubMed, DOI )

  47. Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS ONE. 2016.10; 11 (10): e0165339. ( PubMed, DOI )

  48. Fumio Goto, Sei Kakinuma, Masato Miyoshi, Tomoyuki Tsunoda, Shun Kaneko, Ayako Sato, Yu Asano, Satoshi Otani, Seishin Azuma, Hiroko Nagata, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Mina Nakagawa, Yasuhiro Asahina, Mamoru Watanabe. Bone morphogenetic protein-4 modulates proliferation and terminal differentiation of fetal hepatic stem/progenitor cells. Hepatol. Res.. 2016.09; 47 (9): 941-952. ( PubMed, DOI )

  49. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Masato Miyoshi, Tomoyuki Tsunoda, Sayuri Nitta, Yu Asano, Hiroko Nagata, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Hiromitsu Nakauchi, Hironori Nishitsuji, Saneyuki Ujino, Kunitada Shimotohno, Masashi Iwamoto, Koichi Watashi, Takaji Wakita, Mamoru Watanabe. Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci Rep. 2016.07; 6 29358. ( PubMed, DOI )

  50. Seishin Azuma, Yasuhiro Asahina, Yuki Nishimura-Sakurai, Sei Kakinuma, Shun Kaneko, Hiroko Nagata, Fumio Goto, Satoshi Ootani, Fukiko Kawai-Kitahata, Miki Taniguchi, Miyako Murakawa, Takako Watanabe, Megumi Tasaka-Fujita, Yasuhiro Itsui, Mina Nakagawa, Mamoru Watanabe. Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol. Res.. 2016.04; 46 (4): 312-319. ( PubMed, DOI )

  51. Miki Taniguchi, Megumi Tasaka-Fujita, Mina Nakagawa, Takako Watanabe, Fukiko Kawai-Kitahata, Satoshi Otani, Fumio Goto, Hiroko Nagata, Shun Kaneko, Sayuri Nitta, Miyako Murakawa, Yuki Nishimura-Sakurai, Seishin Azuma, Yasuhiro Itsui, Kenichi Mori, Shintaro Yagi, Sei Kakinuma, Yasuhiro Asahina, Mamoru Watanabe. Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. J Clin Transl Hepatol. 2016.03; 4 (1): 5-11. ( PubMed, DOI )

  52. Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu, Hiroshi Yotsuyanagi. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. Hepatol. Res. 2016.02; 46 (2): 129-165. ( PubMed, DOI )

  53. Satoshi Otani, Sei Kakinuma, Akihide Kamiya, Fumio Goto, Shun Kaneko, Masato Miyoshi, Tomoyuki Tsunoda, Yu Asano, Fukiko Kawai-Kitahata, Sayuri Nitta, Toru Nakata, Ryuichi Okamoto, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Yasuhiro Asahina, Tomoyuki Yamaguchi, Naohiko Koshikawa, Motoharu Seiki, Hiromitsu Nakauchi, Mamoru Watanabe. Matrix metalloproteinase-14 mediates formation of bile ducts and hepatic maturation of fetal hepatic progenitor cells. Biochem. Biophys. Res. Commun.. 2016.01; 469 (4): 1062-1068. ( PubMed, DOI )

  54. Yasuhiro Asahina, Mamoru Watanabe. Need for appropriate programs for prevention of hepatitis B infection: Lessons from the latest nationwide survey in Japan. J. Gastroenterol. Hepatol. 2016.01; 31 (1): 12-13. ( PubMed, DOI )

  55. Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shinji Tanaka, Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Satoshi Otani, Miki Taniguchi, Fumio Goto, Hiroko Nagata, Shun Kaneko, Megumi Tasaka-Fujita, Yuki Nishimura-Sakurai, Seishin Azuma, Yasuhiro Itsui, Mina Nakagawa, Minoru Tanabe, Shinichi Takano, Mitsuharu Fukasawa, Minoru Sakamoto, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J. Gastroenterol. 2015.11; ( PubMed, DOI )

  56. Nobuharu Tamaki, Masayuki Kurosaki, Mayu Higuchi, Hitomi Takada, Natsuko Nakakuki, Yutaka Yasui, Shoko Suzuki, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Shintaro Ogawa, Yasuhito Tanaka, Yasuhiro Asahina, Namiki Izumi. Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS ONE. 2015.09; 10 (9): e0137351. ( PubMed, DOI )

  57. Megumi Tasaka-Fujita, Nao Sugiyama, Wonseok Kang, Takahiro Masaski, Asako Murayama, Norie Yamada, Ryuichi Sugiyama, Senko Tsukuda, Koichi Watashi, Yasuhiro Asahina, Naoya Sakamoto, Takaji Wakita, Eui-Cheol Shin, Takanobu Kato. Amino acid polymorphisms in hepatitis C virus core affect infectious virus production and major histocompatibility complex class I molecule expression. Sci Rep. 2015.09; 5 13994. ( PubMed, DOI )

  58. Goki Suda, Yoshiya Yamamoto, Astushi Nagasaka, Ken Furuya, Mineo Kudo, Yoshimichi Chuganji, Yoko Tsukuda, Seiji Tsunematsu, Fumiyuki Sato, Katsumi Terasita, Masato Nakai, Hiromasa Horimoto, Takuya Sho, Mitsuteru Natsuizaka, Kouji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Yasuyuki Fujita, Riichiro Abe, Miki Taniguchi, Mina Nakagawa, Yasuhiro Asahina, Naoya Sakamoto, . Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. Hepatol. Res. 2015.08; 45 (8): 837-845. ( PubMed, DOI )

  59. Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Naoya Sakamoto, Sayuri Nitta, Akiko Kusano-Kitazume, Takako Watanabe, Fukiko Kawai-Kitahata, Satoshi Otani, Miki Taniguchi, Fumio Goto, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 2015.06; 30 (6): 1075-1084. ( PubMed, DOI )

  60. Nobutoshi Komatsu, Utaroh Motosugi, Shinya Maekawa, Kuniaki Shindo, Minoru Sakamoto, Mitsuaki Sato, Akihisa Tatsumi, Mika Miura, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Mitsuharu Fukasawa, Tomoyoshi Uetake, Masahiko Ohtaka, Tadashi Sato, Yasuhiro Asahina, Masayuki Kurosaki, Namiki Izumi, Tomoaki Ichikawa, Tsutomu Araki, Nobuyuki Enomoto. Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging. Hepatol Res. 2014.12; 44 (13): 1339-1346. ( PubMed, DOI )

  61. Nobuharu Tamaki, Masayuki Kurosaki, Shuya Matsuda, Masaru Muraoka, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J. Gastroenterol. 2014.11; 49 (11): 1495-1503. ( PubMed, DOI )

  62. Yoshihito Kano, Sei Kakinuma, Fumio Goto, Seishin Azuma, Yuki Nishimura-Sakurai, Yasuhiro Itsui , Mina Nakagawa, Atsushi Kudo, Minoru Tanabe, Susumu Kirimura, Tomonori Amano, Takashi Ito , Takumi Akashi, Yasuhiro Asahina, Mamoru Watanabe. Primary Hepatic Neuroendocrine Carcinoma with a Cholangiocellular Carcinoma Component in One Nodule. Clinical Journal of Gastroenterology. 2014.10; 7 449-454.

  63. Yoshihito Kano, Sei Kakinuma, Fumio Goto, Seishin Azuma, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Mina Nakagawa, Atsushi Kudo, Minoru Tanabe, Susumu Kirimura, Tomonori Amano, Takashi Ito, Takumi Akashi, Yasuhiro Asahina, Mamoru Watanabe. Primary hepatic neuroendocrine carcinoma with a cholangiocellular carcinoma component in one nodule. Clin J Gastroenterol. 2014.10; 7 (5): 449-454. ( PubMed, DOI )

  64. Kaoru Tsuchiya, Yasuhiro Asahina, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi. Reply: To PMID 24734314. Liver Transpl. 2014.09; 20 (9): 1152. ( PubMed, DOI )

  65. Yasuhiro Asahina, Kaoru Tsuchiya, Namiki Izumi. Reply: To PMID 23564522. Hepatology. 2014.08; 60 (2): 764. ( PubMed, DOI )

  66. Yasuhiro Iizuka, Hideki Sakai, Konomi Kobayashi, Kazue Iizuka, Eri Ito, Nahoko Mochizuki, Yasuhiro Asahina, Mamoru Watanabe. A case of chronic hepatitis B managed with continued adefovir despite treatment-related Fanconi syndrome and osteomalacia. Nihon Shokakibyo Gakkai Zasshi. 2014.08; 111 (8): 1618-1623. ( PubMed )

  67. Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Mina Nakagawa, Sei Kakinuma, Mamoru Watanabe, Namiki Izumi. Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. J. Gastroenterol. 2014.07; 49 (7): 1152-1162. ( PubMed, DOI )

  68. Nobuharu Tamaki, Masayuki Kurosaki, Shuya Matsuda, Toru Nakata, Masaru Muraoka, Yuichiro Suzuki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Kotaro Matsunaga, Kazuhiro Taki, Yasuhiro Asahina, Namiki Izumi. Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. Hepatol Res. 2014.07; 44 (7): 720-727. ( PubMed, DOI )

  69. Hiroyuki Nakanishi, Masayuki Kurosaki, Kaoru Nakanishi, Kaoru Tsuchiya, Takamasa Noda, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Jun Itakura, Kimitaka Anami, Yasuhiro Asahina, Nobuyuki Enomoto, Teruhiko Higuchi, Namiki Izumi. Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. Hepatol Res. 2014.03; 44 (3): 319-326. ( PubMed, DOI )

  70. Kaoru Tsuchiya, Yasuhiro Asahina, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi. Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl. 2014.03; 20 (3): 291-297. ( PubMed )

  71. Nao Nishida, Hiromi Sawai, Koichi Kashiwase, Mutsuhiko Minami, Masaya Sugiyama, Wai-Kay Seto, Man-Fung Yuen, Nawarat Posuwan, Yong Poovorawan, Sang Hoon Ahn, Kwang-Hyub Han, Kentaro Matsuura, Yasuhito Tanaka, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi, Jong-Hon Kang, Shuhei Hige, Tatsuya Ide, Kazuhide Yamamoto, Isao Sakaida, Yoshikazu Murawaki, Yoshito Itoh, Akihiro Tamori, Etsuro Orito, Yoichi Hiasa, Masao Honda, Shuichi Kaneko, Eiji Mita, Kazuyuki Suzuki, Keisuke Hino, Eiji Tanaka, Satoshi Mochida, Masaaki Watanabe, Yuichiro Eguchi, Naohiko Masaki, Kazumoto Murata, Masaaki Korenaga, Yoriko Mawatari, Jun Ohashi, Minae Kawashima, Katsushi Tokunaga, Masashi Mizokami. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. PLoS ONE. 2014.02; 9 (2): e86449. ( PubMed, DOI )

  72. Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology. 2014.01; 86 (1): 53-62. ( PubMed, DOI )

  73. Asahina Y, HayashinN, Hiramatsu N, Izumi N, Koike K, Kumada H, Kurosaki M,Oketani M, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H,Yotsuyanagi H. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014.01; 44 Suppl S1 1-58. ( PubMed, DOI )

  74. Kaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, Masaru Muraoka, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer. 2014.01; 120 (2): 229-237. ( PubMed, DOI )

  75. Yasuhiro Asahina, Kaoru Tsuchiya, Takashi Nishimura, Masaru Muraoka, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto, Mina Nakagawa, Sei Kakinuma, Mamoru Watanabe, Namiki Izumi. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013.10; 58 (4): 1253-1262. ( PubMed, DOI )

  76. Kei Kiyohashi, Sei Kakinuma, Akihide Kamiya, Naoya Sakamoto, Sayuri Nitta, Hideto Yamanaka, Kouhei Yoshino, Junko Fujiki, Miyako Murakawa, Akiko Kusano-Kitazume, Hiromichi Shimizu, Ryuichi Okamoto, Seishin Azuma, Mina Nakagawa, Yasuhiro Asahina, Naoki Tanimizu, Akira Kikuchi, Hiromitsu Nakauchi, Mamoru Watanabe. Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor cells in mice. Hepatology. 2013.06; 57 (6): 2502-2513. ( PubMed, DOI )

  77. Kusano-Kitazume A, Sakamoto N, Okuno Y, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyohashi K, Nitta S, Murakawa M, Azuma S, Nishimura-Sakurai Y, Hagiwara M, Watanabe M. Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication. Antimicrob Agents Chemother. 2012.03; 56 (3): 1315-1323. ( PubMed, DOI )

  78. Funaoka Y, Sakamoto N, Nakagawa M, Kakinuma S, Suda G, Watanabe T, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol. 2011.06; 85 5986-5994. ( PubMed, DOI )

  79. Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Hige S, Ito Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol. 2011.03; 83 871-878. ( PubMed, DOI )

  80. Yamamoto M, Sakamoto N, Nakamura T, Itsui Y, Nakagawa M, Nishimura-Sakurai Y, Kakinuma S, Azuma S, Kato T, Wakita T, Watanabe M. Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture. Hepatology Res. 2011.03; 41 258-269. ( PubMed, DOI )

  81. Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N, Kiyohashi K, Watanabe T, Funaoka Y, Ueyama M, Nakagawa M, Koshikawa N, Seiki M, Nakauchi H, Watanabe M. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun. 2011.03; 406 134-140. ( PubMed, DOI )

  82. Masayuki Kurosaki, Yasuhito Tanaka, Nao Nishida, Naoya Sakamoto, Nobuyuki Enomoto, Masao Honda, Masaya Sugiyama, Kentaro Matsuura, Fuminaka Sugauchi, Yasuhiro Asahina, Mina Nakagawa, Mamoru Watanabe, Minoru Sakamoto, Shinya Maekawa, Akito Sakai, Shuichi Kaneko, Kiyoaki Ito, Naohiko Masaki, Katsushi Tokunaga, Namiki Izumi, Masashi Mizokami. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol.. 2011.03; 54 (3): 439-448. ( PubMed, DOI )

  83. Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M:. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Antiviral Therapy. 2011; 16 1081-1091. ( PubMed, DOI )

  84. Itsui Y, Sakamoto N, Kakinuma S, Nakagawa M, Sekine-Osajima Y, Tasaka-Fujita M, Nishimura-Sakurai Y, Suda G, Karakama Y, Mishima K, Yamamoto M, Watanabe T, Ueyama M, Funaoka Y, Azuma S, Watanabe M. Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein Hepatology. 2009.12; ( PubMed, DOI )

  85. Kanazawa N, Kurosaki M, Sakamoto N, Enomoto N, Itsui Y, Yamashiro T, Tanabe Y, Maekawa S, Nakagawa M, Chen CH, Kakinuma S, Oshima S, Nakamura T, Kato T, Wakita T, Watanabe M. Regulation of hepatitis C virus replication by interferon regulatory factor 1 J Virol. 2004.09; 78 (18): 9713-9720. ( PubMed, DOI )

▼display all

Conference Activities & Talks 【 display / non-display

  1. Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Ryuichi Okamoto. Liver stiffness stratify the disease progression and hepatocellular carcinoma predictive risk score on chronic hepatitis B patients. JDDW2023 2023.11.03

  2. Mina Nakagawa, Miyako Murakawa, Masato Miyoshi, Shun Kaneko, Fukiko Kawai-Kitahata, Sayuri Nitta, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto. Factors associated with HCC development and patients’ survival in patients with an SVR. The 3rd JSH International Liver Conference 2023.09.07

  3. Yasuhiro Asahina. HCC development and surveillance after SVR. JDDW 2022, JSH-AASLD joint symposium 2022.10.27

  4. Mina Nakagawa, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhiro Asahina. Factors associated with HCC development and patients’ survival in patients with an SVR. JSH International Liver Conference 2021 2021.10.03

  5. Fukiko Kawai-Kitahata, Yasuhiro Asahina , Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Masato Miyoshi, Ayako Sato, Jun Tsuchiya, Taro Shimizu, Eiko Takeichi, Mina Nakagawa, Yasuhiro Itsui, Seishin Azuma, Shinji Tanaka , Minoru Tanabe, Shinya Maekawa, Nobuyuki Enomoto and Mamoru Watanabe. Comprehensive analysis of cancer-related genes and aav/hepatitis b virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis b virus infection. EASL The Digital International Liver Congress 2020 2020.08.28 Web開催

  6. Yasuhiro Asahina. Do DAA therapy result in an increased risk of hepatocarcinogenesis?. Asian Pacific Digestive Week 2019 2019.12.13 Kolata(India)

  7. Yasuhiro Asahina, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma. Comprehensive analysis of cancer gene mutations and viral integration in hepatocellular carcinoma arising from non-fibrotic liver. AASLD The Liver Meeting 2019 2019.11.10 Boston(USA)

  8. Yasuhiro Asahina. Prevention and Risk for Liver Cancer after Anti-Viral Therapy in Patients with HBV/HCV. JSH International Liver Conference 2019.10.02 Osaka(Japan)

  9. MIna Nakagawa, Yasuhiro Asahina, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Msato Miyosh, Emi Inoue, Fukiko Kawai-Kitahata, MIyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Makoto Tomita, Mamoru Watanabe. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. EASL, The International Liver Congress 2019 2019.04.13 Messe Wien Congress and Exhibition Center(Vienna (Austria))

  10. Miyako Murakawa, Yasuhiro Asahina, Emi Inoue, Mina Nakagawa, Jun Tuchiya, Ayako Sato, Masato Miyoshi, Tomoyuki Tsunoda, Fukiko Kitahata-Kawai, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe. The association of serum IFN-lambda 3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents . EASL, The International Liver Congress 2019 2019.04.13 Vienna (Austria)

  11. Asahina Y. Increased risk of HCC following DAA: fact or fiction? / Follow up strategy after SVR in chronic hepatitis C. Asian Pacific Digestive Week 2018 2018.11.16 Seoul(Korea)

  12. Nitta S, Kato T, Tuchiya J, Sato A, Tsunoda T, Miyoshi M, Inoue- Shinomiya E, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The Characteristic and the Anti-HCV Reagents Susceptibility Analysis of NS5A Resistance-Associated Substitutions (RAS) Detected after Daa Treatment Failure Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA)

  13. Nakagawa M, Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tomita M, Watanabe M.. Post-Treatment M2BPGi Level Is Useful for Predicting HCC Occurrence and Recurrence after Viral Eradication in Chronic Hepatitis C Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA)

  14. Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Kakinuma S, Watanabe M. Gene Mutational Profile and Viral Integration in Hepatocellular Carcinoma with or without HBV/HCV Suppression. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco(USA)

  15. Nitta S, Kato T, Tuchiya J, Shinomiya-Inoue E, Sato A, Tsunoda T, Miyoshi M, Kitahata-Kawai F, Murakawa M, Istui Y, Azuma S, Nakagawa M, Kakinuma S, Asahina Y. The in vitro analysis of NS5A resistance-associated substitutions (RAS) observed in DAA treatment failure patients. 25th International Symposium on Hepatitis C Virus and Related Viruses 2018.10.09 Dublin(Ireland)

  16. Asahina Y, Kakinuma S . HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells . EASL, The International Liver Congress 2018 2018.04.14 Paris(France)

  17. Kitahata-Kawai F, Asahina Y. Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/A AV integration. . EASL, The International Liver Congress 2018 2018.04.14 Paris(France)

  18. Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Wang CY, Llewellyn J, Osinusi A, Svarovskaia J, Mo H, Crans G, Chuang WL, Chen PJ, Enomoto N. Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Studies. 27th Annual Conference of the Asian Pacific Association for the Study of the Liver 2018.03.15 Dehli(India)

  19. Asahina Y. Host genome mutations and HBV integration in HCC patients with HBV infection. 36th US-Japan Hepatitis Panel Meeting 2018.01.10 Shenzhen(China)

  20. 朝比奈靖浩. Gap between real world data and the clinical trial with DAA for HCV. TASL2017 2017.12.10 台湾

  21. 朝比奈靖浩. Occurrence and recurrence of hepatocellular carcinoma (HCC) in HCV patients treated with direct acting antiviral agents.. KDDW2017 2017.11.23 Seoul (Korea)

  22. Nakagawa M, Asahina Y, Nagata H, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M. Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - propensity score-matched analysis of a prospective database -. AASLD, The Liver Meeting 2017 2017.10.22 Washington D.C (USA)

  23. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Nitta S, Sato A, Asano Y, Nagata H, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A novel culture model for coinfection of hepatitis B and hepatitis C viruses using human induced pluripotent stem cell–derived hepatic cells for analyses of changes in host-innate immune responses . AASLD The Liver Meeting 2017 2017.10.22 Washington DC

  24. Nitta S, Murakawa M, Kato T, Sato A, Tsunoda T, Miyoshi M, Asano Y, Kaneko S, Nagata H, Kawai-Kitahata F, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The analysis of NS5A Resistance-Associated Substitutions (RAS): In vitro study of NS5A recombinant hepatitis C in infectious cell culture system for various RAS detected after treatment failure in chronic hepatitis C patients . AASLD The Liver Meeting 2017 2017.10.21 Walter E. Washington Convention Center(Washington D.C, USA)

  25. Murakawa M, Asahina Y, Nakagawa M, Nitta S, Kawai-Kitahata F, Nagata H, Kaneko S, Asano Y, Miyoshi M, Tsunoda T, Inoue-Shinomiya E, Sato A, Itsui Y, Kakinuma S, Azuma S, Watanabe M. On-treatment higher levels of alpha-fetoprotein and M2BPGi are associated with development of hepatocellular carcinoma during nucleos(t)ide analog therapy in patients with HBV chronic infection. AASLD, The Liver Meeting 2017 2017.10.21 Washington DC

  26. HCC with or without viral suppression and new predictive biomarkers.. Taiwan Digestive Diseases Week 2017 2017.10.01

  27. Azuma S, Asahina Y, Kakinuma S, Azuma K, Watanabe M.. Diabetic retinopathy as a risk factor associated with development of hepatocellular carcinoma in non-alcoholic fatty liver disease.. Asian Pacific Digestive Week 2017.10.01

  28. Seishin Azuma, Yasuhiro Asahina, Sei Kakinuma, Keiko Azuma, Mamoru Watanabe. Diabetic retinopathy as a risk factor associated with development of hepatocellular carcinoma in non-alcoholic fatty liver disease. Asian Pacific Digestive Week 2017 2017.09.25 香港

  29. Kawai-Kitahata F, Asahina Y, Kakinuma S, Murakawa M, Niita S, Nagata H, Kaneko S, Otani S, Miyoshi M, Tsunoda T, Sato A, Nakagawa M, Itsui Y, Azuma S, Tanaka S, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection. EASL The International Liver Congress 2017 2017.04.20 Amsterdam

  30. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Masato Miyoshi, Tomoyuki Tsunoda, Sayuri Nitta, Ayako Sato, Yu Asano, Hiroko Nagata, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. Genetically modified human induced pluripotent stem cell-derived hepatic progenitor-like cell lines as a model for interaction between hepatitis B virus and host cells. AASLD The Liver meeting 2016 2016.11.11 Boston(USA)

  31. Wai-Kay Seto , Yasuhiro Asahina , Cheng-Yuan Peng , Carol Stanciu , Djamal Abdurakhmanov , John F. Flaherty , Kyungpil Kim , Anuj Gaggar , Mani Subramanian, Fehmi Tabak, Tuan T. Nguyen, Henry Lik-Yuen Chan. Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Com-pared With Tenofovir disoproxil fumarate. AASLD The Liver meeting 2016 2016.11.11 Boston(USA)

  32. Seto WK, Asahina Y, Peng CY, Stanciu C, Abdurakhmanov D, Flaherty JF, Kim K, Gaggar A, Subramanian M, Tabak F, Nguyen TT, Chan HLY.. Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared With Tenofovir disoproxil fumarate.. 2016.11.11

  33. Asahina Y. 【International Session(Symposium)1】Genomics of hepatocellular carcinoma: Hepatitis virus infection and hepatocarcinogenesis. Chair . JDDW2016 2016.11.03 Kobe Cinvention Center(Kobe JAPAN)

  34. Asahina Y. Recent progress in anti-HCV therapy and challenges toward HCC eradication.. Academic Forum of Liver Disease in Northeast China and the Annual Convention for the Study of Liver Diseases in Jilin Province in 2016. 2016.10.29 Changchun(China)

  35. Asahina Y. Hepatocarcinogenesis after hepatitis C viral eradication.. The 10th APASL Single Topic Conference 2016.06.08 Kaoshiung(Taiwan)

  36. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H , Goto F, Otani S, Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A new model for studying interaction between hepatitis B virus and host cells derived from human induced pluripotent stem cells. EASL The International Liver Congress 2016 2016.04.14 Barcelona(Spain)

  37. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H , Goto F, Otani S, Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A Model for Interaction between HBV and Host Cells Derived from Human Induced Pluripotent Stem Cells. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  38. Asahina Y. 【HCV 2】Chair . The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  39. Asahina Y. 【HCV 5】Chair. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  40. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Otani S, Goto F, Nagata H, Kaneko S, Asano Y, Miyoshi M, Tsunoda T, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  41. Nagata H, Sakurai Y, Nakagawa M, Kakinuma S, Azuma S, Murakawa M, Nitta S, Itsui Y, Asahina Y, Watanabe M. Serial changes in M2BPGi levels as predictors of fibrosis and HCC in chronic hepatitis C. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  42. Nitta S, Asahina Y, Wakita T, Kato T. In vitro characterization and drug sensitivity analysis for HCV NS5A resistance-associated variants. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir, Tokyo(JAPAN)

  43. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Sayuri Nitta, Tomoyuki Tsunoda, Masato Miyoshi, Hiroko Nagata, Fumio Goto, Satoshi Otani, Miyako Murakawa, Fukiko Kawai-Kitahata, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. Human induced pluripotent stem cell-derived hepatic progenitor-like cells and hepatocyte-like cells as a model for interaction between hepatitis B virus and host cells. AASLD The Liver Meeting 2015 2015.11.16 San Francisco, CA

  44. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Goto F, Nagata H, Kaneko S, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Maekawa S, Enomoto N, Watanabe M. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. AASLD The Liver Meeting 2015 2015.11.14 San Francisco, CA

  45. Sayuri Nitta, Yasuhiro Asahina, Takaji Wakita, Takanobu Kato. Effects of Resistance Mutations of NS5A Inhibitor on Viral Production and Susceptibility to Anti-HCV Reagents in Recombinant Hepatitis C Viruses with NS5A of Genotype 1b. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  46. Hiroko Nagata, Yasuhiro Itsui, Fukiko Kawai-Kitahata, Shun Kaneko, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Yasuhiro Asahina. Variations of the host genome and interaction of hepatitis B viral X protein associated with hepatocarcinogenesis. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  47. Takako Watanabe, Yasuhiro Asahina, Mina Nakagawa, Sei Kakinuma, Yasuhiro Itsui, Hiroko Nagata, Miyako Murakawa, Fukiko Kawai-Kitahata, Mika Miura, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe. Serial change of resistant associated variants during early phase of NS3/4A triple therapy and the final virological outcome: analyses by ultra-deep sequencing technology. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  48. Miyako Murakawa, Yasuhiro Asahina, Fukiko Kawai-Kitahata, Hiroko Nagata, Syun Kaneko, Sayuri Nitta, Takako Watanabe, Yasuhiro Itsui, Mina Nakagawa, Sei Kakinuma, Sayuki Iijima, Yasuhito Tanaka, Mamoru Watanabe, Yujiro Tanaka. Expression of IFNλ4 in liver is closely associated with non-response to antiviral therapy through the regulation of basal expression of ISGs in chronic hepatitis C patients but not in hepatitis B patients. AASLD The Liver Meeting 2015 2015.11.13 San Francisco, CA

  49. Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shun Kaneko, Hiroko Nagata, Fumio Goto, Satoshi Otani, Miki Taniguchi, Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Megumi Tasaka-Fujita, Yuki Nishimura-Sakurai, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma, Shinji Tanaka , Minoru Tanabe, Nobuyuki Enomoto and Mamoru Watanabe. Gene alterations in TERT promoter, CTNNB1, and TP53 are closely associated with development and prognosis of hepatocellular carcinoma : Comprehensive analyses by next generation sequencing technology. The 3rd JSGE International Topic Conference 2015.04.24 Sendai

  50. Asahina Y, Kawai-Kitahata F, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M, Murakawa M, Nitta S, Watanabe T, Tasaka-Fujita M, Nishimura-Sakurai Y, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Tanaka S, Tanabe M, Enomoto N, Watanabe M. Gene alterations in tert promoter, CTNNB1, and TP53 are closely associated with development and prognosis of hepatocellular carcinoma: comprehensive analyses by next generation sequencing technology. 50th The International liver congress 2015, EASL 2015.04.22 Vienna

  51. Murakawa M, Asahina Y, Nakagawa M, Kawai-Kitahata F, Taniguchi M, Nitta S, Watanabe T, Itsui Y, Kakinuma S, Sakamoto N, Watanabe M. Expression of IFNλ4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients. The 65th. Annual Meeting of American Association for the Study of Liver Diseases(AASLD The Liver Meeting 2014) 2014.11.11 Boston

  52. Watanabe T, Asahina Y, Nakagawa M, Kakinuma S, Itsui Y, Taniguchi M, Murakawa M, Nagata H, Miura M, Maekawa S, Enomoto N, Watanabe M. Emergence or selection of resistant associated variant immediately after initiation of the therapy is predictive for failure of direct acting antiviral therapy:ultra-deep sequencing analyses for serial time points. The 65th. Annual Meeting of American Association for the Study of Liver Diseases(AASLD The Liver Meeting 2014) 2014.11.11 Boston

  53. Otani S, Kakinuma S, Watanabe M. Matrix Metalloproteinase-14 regulates the maturation of fetal hepatic stem/progenitor cells in mice. The 65th. Annual Meeting of American Association for the Study of Liver Diseases(AASLD The Liver Meeting 2014) 2014.11.11 Boston

  54. Kawai-Kitahata F, Asahina Y, Kaneko S, Nagata H, Goto F, Otani S, Taniguchi M , Murakawa M , Nitta S, Watanabe T, Itsui Y, Nakagawa M, Kakinuma S, Enomoto N, Watanabe M. Gene alterations in β-catenin and p53/cell cycle control pathway are closely associated with development and prognosis of hepatocellular carcinoma: Comprehensive analyses by next generation sequencing technology. The 65th. Annual Meeting of American Association for the Study of Liver Diseases(AASLD The Liver Meeting 2014) 2014.11.10 Boston

  55. Nakagawa M, Asahina Y, Taniguchi M, Watanabe T, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M. Impact of host and therapeutic factors and resistant associated variants on response to interferon based-direct acting antiviral treatment in difficult-to-treat chronic hepatitis C patients. The 65th. Annual Meeting of American Association for the Study of Liver Diseases(AASLD The Liver Meeting 2014) 2014.11.09 Boston

  56. Otani S, Kakinuma S, Kamiya A, Goto F, Kaneko S, Azuma S, Asahina Y, Watanabe M. Matrix Metalloproteinase-14 controls differentiation of fetal hepatic stem/progenitor cells. Japan Digesive Disease Weeks 2014 2014.10.23 Kobe

  57. 谷口未樹、中川美奈、 朝比奈靖浩 柿沼 晴、東 正新、渡辺貴子、櫻井 幸、村川美也子、大谷賢志、河合富貴子、後藤文男、坂本直哉、渡辺 守. 慢性肝疾患における肝細胞癌とIL-6 の関連. 第49回日本肝臓学会総会 2013.06.06 京王プラザホテル(東京都新宿区)

  58. 新田沙由梨、朝比奈靖浩、柿沼 晴、坂本直哉、渡辺 守. ウイルス肝炎における自然免疫応答抑制メカニズムの解析. Liver Forum in Kyoto 第16回学術集会 2013.03.29 京都

▼display all